Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors
07 Septiembre 2022 - 5:50AM
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”)
(Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on
developing novel drugs for the targeted treatment of
neuropsychiatric disorders, epilepsy, and pain, today announced the
appointment of Doug Williamson to the Company’s Board of Directors
(the “Board”). Dr. Williamson will serve on the Compensation,
Nominating and Corporate Governance, and Audit Committees as an
independent director. Concurrently, Dr. Alan Kozikowski has
resigned from the Board.
“Dr. Williamson has an impressive track record
in developing safe and profitable pharmaceuticals and
biotechnologies for global industry leaders. With his reputation
for generating quality results while improving ROI and building
high-performance, engaged teams, we are thrilled to welcome Dr.
Williamson to the Board,” stated Ian McDonald, CEO and Co-founder
of Bright Minds Biosciences.
Dr. Kozikowski, a significant co-founder and scientific
contributor to Bright Minds Biosciences, developed much of the
technology on which the Company is based, including the invention
of BMB-101, the later work being done during his tenure as
Professor of Medicinal Chemistry at the University of Illinois at
Chicago. BMB-101 is the subject of a patent licensed by Bright
Minds Biosciences from the University of Illinois.
“We remain grateful for Dr. Kozikowski’s service and wish him
well in his future endeavors,” said McDonald.
About Dr. Williamson
Dr. Williamson has more than 25 years of
scientific, clinical, and medical experience and currently serves
as Senior Vice President, Head of U.S. R&D and Deputy Global
Chief Medical Officer for Lundbeck. During his time at Lundbeck, he
has overseen multiple cross-functional teams across clinical
development and operations, medical affairs, value evidence (health
outcomes), patient safety, clinical pharmacology, and regulatory
affairs. He also led the transformation of the U.S. and Canadian
R&D organizations and co-led the task force in setting U.S.
policy for COVID precautions and remote working.
Prior to Lundbeck, Dr. Williamson served as Vice
President, Global Head Therapeutic Area leadership at Parexel
International, where he developed and instituted therapeutic area
strategies to guide new business acquisitions. He was also the
functional head of the medical group across all therapeutic areas.
Previously, Dr. Williamson held multiple roles at Eli Lilly and
Company, including Head, Early Phase Clinical Development
Neuroscience, where he oversaw the clinical development of all
novel molecules in the psychiatry, pain, and neurodegeneration
portfolio. Dr. Williamson earned a Bachelor of Medicine and Surgery
(MBChB) degree from Edinburgh University in Scotland and is a
member of the Royal College of Psychiatrists.
In connection with his appointment to the Board
of Directors, the Company granted Dr. Williamson an aggregate of
80,000 stock options (the “Options”) to purchase 80,000 common
shares in the capital of the Company (the “Shares”) pursuant to the
terms of the Company’s share option plan dated July 1, 2020. The
Options are exercisable at an exercise price of $2.46 per share for
a period of 5 years from the date of grant. The Options are subject
to vesting, beginning with 25% vested at the time of the grant, and
25% every 12 months thereafter.
About Bright Minds
Bright Minds is focused on developing novel
transformative treatments for neuropsychiatric disorders, epilepsy,
and pain. Bright Minds has a portfolio of next-generation serotonin
agonists designed to target neurocircuit abnormalities that are
responsible for difficult to treat disorders such as resistant
epilepsy, treatment resistant depression, PTSD, and pain. The
Company leverages its world-class scientific and drug development
expertise to bring forward the next generation of safe and
efficacious drugs. Bright Minds’ drugs have been designed to
potentially retain the powerful therapeutic aspects of psychedelic
and other serotonergic compounds, while minimizing the side
effects, thereby creating superior drugs to first-generation
compounds, such as psilocybin.
Investor Contact:Lisa WilsonE:
lwilson@insitecony.comT: 917-543-9932
Neither Canadian Securities Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the Canadian Securities Exchange) accepts
responsibility for the adequacy or accuracy of this release.
The securities of the Company referred to in
this news release have not been and will not be registered under
the United States Securities Act of 1933, as amended (the
“U.S. Securities Act”), or any state securities
laws. Accordingly, the securities of the Company may not be offered
or sold within the United States unless registered under the U.S.
Securities Act and applicable state securities laws or pursuant to
an exemption from the registration requirements of the U.S.
Securities Act and applicable state securities laws. This news
release does not constitute an offer to sell or a solicitation of
any offer to buy any securities of the Company in any jurisdiction
in which such offer, solicitation or sale would be unlawful.
Bright Minds Biosciences (NASDAQ:DRUG)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Bright Minds Biosciences (NASDAQ:DRUG)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024